These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11824485)

  • 21. Drug treatment of schizophrenia and delusional disorder in late life.
    Howard R
    Int Psychogeriatr; 1996; 8(4):597-608. PubMed ID: 9147173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z; Britvić D; Vuković O; Ille T
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacologic approach to negative symptoms in schizophrenia].
    Jalenques I
    Encephale; 1995 Jun; 21 Spec No 3():35-40. PubMed ID: 7628340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involuntary disorders of movement in chronic schizophrenia--the role of the illness and its treatment.
    Owens DG
    Psychopharmacology Suppl; 1985; 2():79-87. PubMed ID: 2860663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine-induced tardive dyskinesia and hypothyroidism.
    Mendhekar DN; Duggal HS
    J Neuropsychiatry Clin Neurosci; 2006; 18(2):245-6. PubMed ID: 16720805
    [No Abstract]   [Full Text] [Related]  

  • 26. Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases.
    Friedman JH
    Mov Disord; 1994 May; 9(3):321-4. PubMed ID: 7913739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.
    Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A
    Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors affecting rehospitalisation rates of chronic schizophrenic patients living in the community.
    Soni SD; Gaskell K; Reed P
    Schizophr Res; 1994 May; 12(2):169-77. PubMed ID: 8043527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
    Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
    Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adherence to neuroleptic treatment of schizophrenic patients].
    Blondiaux I; Alagille M; Ginestet D
    Encephale; 1988; 14(6):431-8. PubMed ID: 2906607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extrapyramidal motor abnormalities associated with late-life psychosis.
    Caligiuri MP; Lohr JB; Panton D; Harris MJ
    Schizophr Bull; 1993; 19(4):747-54. PubMed ID: 7905662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Psychological effects of previous treatment experiences with neuroleptics].
    Bossert S; Dose M; Emrich HM; Garcia D; Junker M; Raptis K; Weber MM
    Nervenarzt; 1990 May; 61(5):301-5. PubMed ID: 1972785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The initial dysphoric reaction (IDR) to the first dose of neuroleptics].
    Schimmelmann BG; Schacht M; Perro C; Lambert M
    Nervenarzt; 2004 Jan; 75(1):36-43. PubMed ID: 14722660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight.
    Garavan J; Browne S; Gervin M; Lane A; Larkin C; O'Callaghan E
    Compr Psychiatry; 1998; 39(4):215-9. PubMed ID: 9675506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
    Shriqui CL
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
    Kao YC; Liu YP
    Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic.
    Pan PC; Tantam D
    Acta Psychiatr Scand; 1989 Jun; 79(6):564-70. PubMed ID: 2569803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
    Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
    Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Negative symptoms of schizophrenia and compliance with medication.
    Tattan TM; Creed FH
    Schizophr Bull; 2001; 27(1):149-55. PubMed ID: 11215543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.